Singapore markets open in 8 hours 15 minutes

Straits Times Index
3,348.87
+12.28(+0.37%)
S&P 500
5,248.00
-29.51(-0.56%)
Dow
38,290.84
-395.48(-1.02%)
Nasdaq
16,709.84
-25.18(-0.15%)
Bitcoin USD
69,144.50
+1,125.44(+1.65%)
CMC Crypto 200
1,486.46
+18.52(+1.26%)

NTLA Oct 2024 20.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

5.80

0.00

(0.00%)

As of 01:05PM EDT. Market open.

GlobeNewswire
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across a
Zacks
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Simply Wall St.
Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) just released its quarterly report and things are looking bullish. Results...